Xconomy National

Archives

by in

Entry	Author	Date	Location
A Sweet Deal: How Amira Reinvented Itself as a Drug Discovery Engine	Bruce V. Bigelow	12/23/11	San Diego
Epizyme Takes $6M Upfront in Cancer Drug Deal with Eisai	Ryan McBride	03/10/11	Boston
San Diego’s Leading Ventures Takes on Commercialization of Bioengineering Breakthroughs	Bruce V. Bigelow	02/08/11	San Diego
Xoma Nabs $35M Upfront Deal	Luke Timmerman	01/04/11	San Francisco
Anthera, On a Lean Budget, Seeks to Tap Big Heart Attack Market By Blocking Inflammation	Luke Timmerman	11/16/10	San Francisco
Aileron Inks Deal with Roche, Worth Up to $1.1B, to Develop Stapled Peptide Drugs	Gregory T. Huang	08/24/10	Boston
Alder Reduces Anemia in Cancer Study	Luke Timmerman	06/06/10	Seattle
Glaxo’s SR One Injects Pharma Bucks into $22M Round for Constellation Pharma	Ryan McBride	06/02/10	Boston
How Internet Pioneer Larry Smarr Lost 20 Pounds by Becoming a “Quantified Self”	Luke Timmerman	05/12/10	San Diego
Accelerator’s MicroRNA Play, Mirina, Forges Ahead With One More Year of Cash	Luke Timmerman	04/26/10	Seattle
Genzyme Expects to Pay $175M to FDA, Westphal Leaves Sirtris to Run GSK Venture Arm, Gelesis Obesity Treatment Passes First Human Trial, & More Boston-Area Life Sciences News	Erin Kutz	04/23/10	Boston
Catabasis, Led by Sirtris Vets, Seeks to Fight Diabetes by Controlling Inflammation	Luke Timmerman	04/21/10	Boston
Ascent Changes to Anchor	Erin Kutz	03/30/10	Boston
Flexion Snags Pfizer Bucks, Three Pharma Deals, For New Drug Model	Luke Timmerman	01/29/10	Boston
Omeros Moves Closer To IPO, Sets Price Goal	Luke Timmerman	09/16/09	Seattle
Lankau New CEO at Logical	Ryan McBride	05/11/09	Boston
Pfizer’s VC Leader, Barbara Dalton, on Corporate Venture and Northwest Deal Hunting	Luke Timmerman	03/17/09	Seattle
Calistoga Reunites Icos Execs To Pursue Cancer, Inflammation Drugs	Luke Timmerman	03/11/09	Seattle
Meritage Starts Study of Inflammatory Disease	Luke Timmerman	01/22/09	San Diego
Qwell Pharmaceuticals, Backed by Arch, Raises $7M for New Cancer, Inflammation Drugs	Luke Timmerman	01/06/09	Seattle
Another Next-Generation RNAi Startup Emerges, Makes Big Claims About Its Ability to Silence Bad Genes	Ryan McBride	12/18/08	Boston
Taligen CEO Aims to Develop Drugs For Inflammatory Diseases, Build Company in Cambridge	Luke Timmerman	08/14/08	Boston
Novo Nordisk Returning to Seattle, Hiring 80 People by 2010	Luke Timmerman	08/05/08	Seattle
Page 1 of 1